Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022009207 - METHODS OF TREATING COVID-19 USING CHOLINERGIC AGONISTS, MODIFIED ANTIBODIES AND NASOPHARYNGEAL WASH

Publication Number WO/2022/009207
Publication Date 13.01.2022
International Application No. PCT/IL2021/050835
International Filing Date 07.07.2021
IPC
A61K 31/465 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
465Nicotine; Derivatives thereof
A61K 31/4178 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4178not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61K 9/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 31/221 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
22of acyclic acids, e.g. pravastatin
221with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
A61K 31/55 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
Applicants
  • FARSALINOS, Konstantinos [GR]/[GR]
  • POULAS, Konstantinos [GR]/[GR]
  • ILIOPOULOS, Ilias [GR]/[GR]
  • TZARTOS, John [GR]/[GR]
  • ALMON, Ehud [IL]/[IL]
Inventors
  • FARSALINOS, Konstantinos
  • POULAS, Konstantinos
  • ILIOPOULOS, Ilias
  • TZARTOS, John
  • ALMON, Ehud
  • TZARTOS, Socrates
Agents
  • BRESSLER, Eyal
Priority Data
63/048,66707.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF TREATING COVID-19 USING CHOLINERGIC AGONISTS, MODIFIED ANTIBODIES AND NASOPHARYNGEAL WASH
(FR) MÉTHODES DE TRAITEMENT DE LA COVID-19 À L'AIDE D'AGONISTES CHOLINERGIQUES, D'ANTICORPS MODIFIÉS ET D'UN LAVAGE NASOPHARYNGÉ
Abstract
(EN) The present invention discloses treating COVID-19 by either a single method or a combination of two or more methods. Three of the methods are based on administering a patient compounds characterized by an affinity to bind to nicotinic acetylcholine receptors (nAChRs), or to a conserved viral epitope that binds to the nAChRs, thus, blocking/competing/preventing/reducing virions attachment to cells and the subsequent viral internalization to the cell. The affinity-based compounds comprise of (1) antibodies and (2) nicotinic agonists, muscarinic agonists. A non- affinity based additional method of the present invention is an extensive nasopharyngeal wash configured to reduce a patient viral load.
(FR) La présente invention concerne le traitement de la COVID-19 par une seule méthode ou par une combinaison de deux méthodes ou plus. Trois des méthodes sont basés sur l'administration à un patient de composés caractérisés par une affinité pour se lier aux récepteurs nicotiniques de l'acétylcholine (nAChR), ou à un épitope viral conservé qui se lie aux nAChR, bloquant/entrant en compétition/prévenant/réduisant ainsi la fixation de virions à des cellules et l'internalisation virale qui s'ensuit dans la cellule. Les composés reposant sur l'affinité comprennent (1) des anticorps et (2) des agonistes nicotiniques, des agonistes muscariniques. Une méthode supplémentaire non basée sur l'affinité selon la présente invention consiste en un lavage nasopharyngé poussé conçu pour réduire la charge virale d'un patient.
Latest bibliographic data on file with the International Bureau